Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mortality of hospitalized patients with COVID-19: Effects of treatment options (vitamin D, anticoagulation, isoprinosine, ivermectin) assessed by propensity score matching, retrospective analysis

J. Plasek, J. Dodulik, P. Gai, B. Hrstkova, J. Skrha, L. Zlatohlavek, R. Vlasakova, P. Danko, P. Ondracek, E. Cubova, B. Capek, M. Kollarova, T. Furst, J. Vaclavik

. 2024 ; 168 (1) : 35-43. [pub] 20231204

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24005428

INTRODUCTION: SARS-CoV-2 respiratory infection is associated with significant morbidity and mortality, especially in hospitalized high-risk patients. We aimed to evaluate the effects of treatment options (vitamin D, anticoagulation, isoprinosine, ivermectin) on hospital mortality in non-vaccinated patients during the 2021 spring wave in the Czech Republic. METHODS: Initially, 991 patients hospitalized in the period January 1, 2021, to March 31, 2021, with PCR-confirmed SARS-CoV-2 acute respiratory infection in two university and five rural hospitals were included in the study. After exclusion of patients with an unknown outcome, a total of 790 patients entered the final analysis. The effects of different treatments were assessed in this cohort by means of propensity score matching. RESULTS: Of the 790 patients, 282 patients died in the hospital; 37.7% were male and 33.3% were female. Age, sex, state of the disease, pneumonia, therapy, and several comorbidities were matched to simulate a case-control study. For anticoagulation treatment, 233 cases (full-dose) vs. 233 controls (prophylactic dose) were matched. The difference in mortality was significant in 16 of the 50 runs. For the treatment with isoprinosine, ivermectin, and vitamin D, none of the 50 runs led to a significant difference in hospital mortality. CONCLUSION: Prophylactic-dose anticoagulation treatment in our study was found to be beneficial in comparison with the full dose. Supplementation with vitamin D did not show any meaningful benefit in terms of lowering the hospital mortality. Neither ivermectin nor, isoprinosine was found to significantly decrease hospital mortality.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005428
003      
CZ-PrNML
005      
20250408142743.0
007      
ta
008      
240404s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.045 $2 doi
035    __
$a (PubMed)38050692
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Plášek, Jiří $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Center for Research on Internal Medicine and Cardiovascular diseases, Faculty of Medicine, University of Ostrava, Czech Republic $7 xx0107483
245    10
$a Mortality of hospitalized patients with COVID-19: Effects of treatment options (vitamin D, anticoagulation, isoprinosine, ivermectin) assessed by propensity score matching, retrospective analysis / $c J. Plasek, J. Dodulik, P. Gai, B. Hrstkova, J. Skrha, L. Zlatohlavek, R. Vlasakova, P. Danko, P. Ondracek, E. Cubova, B. Capek, M. Kollarova, T. Furst, J. Vaclavik
520    9_
$a INTRODUCTION: SARS-CoV-2 respiratory infection is associated with significant morbidity and mortality, especially in hospitalized high-risk patients. We aimed to evaluate the effects of treatment options (vitamin D, anticoagulation, isoprinosine, ivermectin) on hospital mortality in non-vaccinated patients during the 2021 spring wave in the Czech Republic. METHODS: Initially, 991 patients hospitalized in the period January 1, 2021, to March 31, 2021, with PCR-confirmed SARS-CoV-2 acute respiratory infection in two university and five rural hospitals were included in the study. After exclusion of patients with an unknown outcome, a total of 790 patients entered the final analysis. The effects of different treatments were assessed in this cohort by means of propensity score matching. RESULTS: Of the 790 patients, 282 patients died in the hospital; 37.7% were male and 33.3% were female. Age, sex, state of the disease, pneumonia, therapy, and several comorbidities were matched to simulate a case-control study. For anticoagulation treatment, 233 cases (full-dose) vs. 233 controls (prophylactic dose) were matched. The difference in mortality was significant in 16 of the 50 runs. For the treatment with isoprinosine, ivermectin, and vitamin D, none of the 50 runs led to a significant difference in hospital mortality. CONCLUSION: Prophylactic-dose anticoagulation treatment in our study was found to be beneficial in comparison with the full dose. Supplementation with vitamin D did not show any meaningful benefit in terms of lowering the hospital mortality. Neither ivermectin nor, isoprinosine was found to significantly decrease hospital mortality.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a COVID-19 $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a ivermektin $x terapeutické užití $7 D007559
650    _2
$a retrospektivní studie $7 D012189
650    12
$a inosin pranobex $7 D007542
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a vitamin D $x terapeutické užití $7 D014807
650    _2
$a tendenční skóre $7 D057216
650    _2
$a vitaminy $7 D014815
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dodulík, Jozef $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0273676
700    1_
$a Gai, Petr $u Department of Pulmonary Medicine and Tuberculosis, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0331032
700    1_
$a Hrstková, Barbora $u Clinic for Infectious diseases, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0276506
700    1_
$a Škrha, Jan $u 3rd Department of Internal Medicine, General University Hospital, Prague $7 xx0226036
700    1_
$a Zlatohlávek, Lukáš, $u 3rd Department of Internal Medicine, General University Hospital, Prague $d 1978- $7 xx0061418
700    1_
$a Vlasáková, Renata $u 3rd Department of Internal Medicine, General University Hospital, Prague $7 xx0331029
700    1_
$a Danko, Peter $u Department of Internal Medicine, Havirov Regional Hospital, Havirov, Czech Republic $7 xx0331031
700    1_
$a Ondráček, Petr $u Department of Internal Medicine, Bilovec Regional Hospital, Bilovec, Czech Republic $7 _AN089543
700    1_
$a Čubová, Eva $u Department of Internal Medicine, Fifejdy Ostrava City Hospital, Ostrava, Czech Republic $7 xx0331030
700    1_
$a Čapek, Bronislav $u Department of Internal Medicine, Associated Medical Facilities, Krnov, Czech Republic $7 xx0234993
700    1_
$a Kollarova, Marie $u Department of Internal Medicine, Trinec Regional Hospital, Trinec, Czech Republic
700    1_
$a Furst, Tomas $u Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University Olomouc, Czech Republic
700    1_
$a Vaclavik, Jan $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Center for Research on Internal Medicine and Cardiovascular diseases, Faculty of Medicine, University of Ostrava, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 1 (2024), s. 35-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38050692 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20240404 $b ABA008
991    __
$a 20250408142740 $b ABA008
999    __
$a ok $b bmc $g 2295211 $s 1215188
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 168 $c 1 $d 35-43 $e 20231204 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK116 $a Pubmed-20240404

Find record

Citation metrics

Archiving options